Premium
PIII‐17
Author(s) -
Krishna R.,
Bergman A. J.,
Larson P.,
Cote J.,
Lasseter K. C.,
Pierre M.,
Wang A. Q.,
Zeng W.,
Chen L.,
Wagner J. A.,
Herman G. A.
Publication year - 2006
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1016/j.clpt.2005.12.225
Subject(s) - sitagliptin , cmax , dipeptidyl peptidase 4 inhibitor , pharmacology , pharmacokinetics , medicine , sitagliptin phosphate , dipeptidyl peptidase 4 , oral administration , crossover study , endocrinology , type 2 diabetes , diabetes mellitus , placebo , alternative medicine , pathology
BACKGROUND Sitagliptin (MK‐0431), an orally active, potent and selective DPP‐IV inhibitor being developed for Type 2 diabetes mellitus, is a substrate for p‐glycoprotein (Pgp). High dose cyclosporine A (CSA) was used as a probe Pgp inhibitor to evaluate the effect of potent Pgp inhibition on sitagliptin PK. METHODS 8 healthy young men received Treatments A (single oral 600 mg dose of CSA[NEORAL™] with a single 100 mg oral sitagliptin dose) and B (single oral 100 mg sitagliptin dose alone) in an open‐label, randomized, 2‐period, crossover study, separated by a 2‐week washout. Pre‐specified bounds of[0.50, 2.00] were used for AUC GMR whether any alterations in MK‐0431 PK was clinically meaningful. RESULTS Sitagliptin with or without CSA was generally well tolerated. Sitagliptin AUC 0‐∞ GMR (1.29) with 90% CI[1.24, 1.34], and C max GMR (1.68) with 90% CI[1.35, 2.08] indicated modest effects by CSA and unlikely to be clinically relevant. There were no meaningful differences in CL r , apparent t 1/2 or C 24hr . CONCLUSIONS This study with high dose CSA confirmed that sitagliptin was a substrate for Pgp. Co‐administration of CSA with sitagliptin only modestly increased C max of sitagliptin without a meaningful effect on overall exposure. Given only modest alterations in PK (i.e., on C max ) with a highly potent Pgp inhibitor, the magnitude of changes in sitagliptin PK with other medications that are Pgp inhibitors, albeit less potent ones, is unlikely to be clinically meaningful. Clinical Pharmacology & Therapeutics (2005) 79 , P63–P63; doi: 10.1016/j.clpt.2005.12.225